# Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

> **NCT00551018** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 218 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Vicriviroc
- **DRUG:** emtricitabine and tenofovir disoproxil fumarate

## Key facts

- **NCT ID:** NCT00551018
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-05
- **Final completion:** 2010-10
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2015-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551018, "Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00551018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*